Search for: [Abstract = "22 patients received planed treatment, 2 patients received the therapy divided into 3 cycles, the other 1 patient received 7 cycles. The most often instituted dose was 100 mCi per treatment cycle. The cycles were repeated every 4 to 9 week, most commonly every 6\-7 week. Two hours before the injection of the labelled somatostatin analogue, the infusion of amino\-acids formula was given to every patient for nephroprotection. The infusion time of the pre\-prepared somatostatin analogue preparation labelled with radioisotope \(manufacturer\: Research and Development IAE Radioisotope Centre Otwock\-Świerk\) was 30 minutes. It was followed by 6\-hour infusion of the amino\-acids. The NHL patients received the dose of 90Y\-Ibritumomab\-tiuxetan \(Zevalin\) calculated based on the platelet count and body mass. If the platelet count \(PLT\) exceeded 150 000 per µl, the patient was administered 15 MBq \(0,4 mCi\) per kg of the body mass. If the PLT was within the range 100 000 – 150 000 per µl, the dose of 11 MBq \(0,3 mCi\) per kg of the body mass was given. The maximum dose was 1200 MBq \(32 mCi\). The radioimmunotherapy was preceded by Rituximab injection \(250 mg per m2 of the BSA\) administered one week earlier. Rituximab injection \(the dose of 250 mg per m2 of the BSA\) was repeated again 4 hours before the treatment with Zevalin. The preparation was labelled with Yttrium isotope in Nuclear Medicine Unit of the Endocrinology Department of University Hospital in Krakow. The radiochemical purity of the pharmaceutical was assessed after the labelling procedure, Zevalin was injected only when its purity was higher than 95%. Every patient with mantle cell lymphoma was given every 21 days 3 to 6 cycles of FCM\+\/\-Rituximab chemotherapy. After first 3 cycles of the therapy the patient was qualified for radioimmunotherapy \(RIT\). If the patient did not fulfill the criteria for RIT, next 3 cycles of the therapy were given. Additional bridging dose of Rituximab was administered if the rise of neutrophil count or PLT count was not observed. The 90Y\-Ibritumomab tiuxetan was not implemented in patients not meeting the criteria of the qualification. Statistical analysis was performed using STATISTICA PL \(version 6.0\) package. After the treatment in subgroup of NET patients no statistically important changes in creatinine level and GFR were observed. After 5 months an increase in creatinine level was noticed \(from 73,37 µmol\/l to 86,63 µmol\/l\). A slightly higher rise in creatinine levels was observed in a small subset of patients with longer, 24\-month follow\-up period. Mean creatinine level was 101,66 µmol\/l. None of the patient showed the signs and symptoms related to the deterioration of the kidney function. However, literature data on the delayed nephrotoxicity suggest that the prolonged observation after the treatment with labelled somatostatin analogues is needed. Only minor changes in complete blood count \(CBC\) were seen after completion of the therapy. Mean haemoglobin level decreased after subsequent therapy cycles. The lowest mean values of haemoglobin \(11,65 g\/dL\) were found during the 4 month after initiation of the treatment \(mean pre\-therapy level was 12,4 g\/dL\). Increase in haemoglobin level was observed 1 month after nadir values were reached. Normal haemoglobin levels or mild anaemia were present in most of the patients. 2 persons developed severe anaemia \(3rd grade of toxicity\) after 1 month after initiation of the treatment and after 3 cycle respectively. Similarly, after subsequent cycles of the therapy decrease in the PLT count was seen, but the mean values were within normal range. Only in 1 patient single measurement of PLT was assessed as the 3 grade toxicity according to WHO.The lowest values of white blood cell count \(WBC\) were seen after 3 and 4 cycle of the treatment. In the subgroup of NET patients WBC decreased by at least one toxicity grade according to WHO in 20 patients. No 4 grade toxicity was observed. Three patients developed 3 grade"]

Number of results: 0